MedPath

Evaluation of an Oral Nutrition Supplement

Not Applicable
Completed
Conditions
Gastrointestinal Tolerance
Registration Number
NCT01902212
Lead Sponsor
Abbott Nutrition
Brief Summary

The objective of this study is to capture gastrointestinal tolerance (GI) information on a nutrient dense oral nutritional supplement (ONS) in healthy elderly subjects.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
25
Inclusion Criteria

Subjects will be eligible for the study if they meet all of the following inclusion criteria:

  • Male or female ≥ 60 and ≤ 90 years of age.
  • Body Mass Index (BMI) > 20 but < 35.
Exclusion Criteria

Subjects will be excluded from the study if they meet any of the following criteria:

  • History of diabetes
  • Antibiotic use within 1 week prior to enrollment
  • Undergone major surgery less than 3 months prior to enrollment.
  • Current active malignant disease or was treated within the last 6 months for cancer.
  • Immunodeficiency disorder.
  • Myocardial infarction within the last 3 months.
  • Chronic obstructive pulmonary disease (COPD).
  • Allergy to any of the ingredients in the study product.
  • Obstruction of the gastrointestinal tract or other major gastrointestinal disease.
  • Dementia, brain metastases, eating disorders, history of significant neurological or psychiatric disorder.
  • Unintentional weight loss or weight gain ≥ 5% in last 4 weeks.
  • Taking medications/dietary supplements/substances that could profoundly modulate metabolism or affect GI motility.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Gastro-Intestinal ToleranceStudy Day (SD) 1-8

Subject questionnaire

Secondary Outcome Measures
NameTimeMethod
ONS ConsumptionSD 1-8

Consumption Record

WeightScreening and SD 8

Trial Locations

Locations (1)

Biofortis Sas

🇫🇷

Saint Herblain, France

Biofortis Sas
🇫🇷Saint Herblain, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.